Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

Cancer

Volumn 120, Issue 15, 2014, Pages 2371-2378

  Miaskowski, Christine ^a   Cooper, Bruce A ^a   Melisko, Michelle ^a   Chen, Lee May ^a   Mastick, Judy ^a   West, Claudia ^a   Paul, Steven M ^a   Dunn, Laura B ^a   Schmidt, Brian L ^b   Hammer, Marilyn ^b   Cartwright, Frances ^b   Wright, Fay ^b   Langford, Dale J ^a   Lee, Kathryn ^a   Aouizerat, Bradley E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

chemotherapy; latent class analysis; precision medicine; quality of life; symptom clusters; symptom profiles

Indexed keywords

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COMORBIDITY; DIGESTIVE SYSTEM CANCER; FEMALE; FUNCTIONAL STATUS; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEMORIAL SYMPTOM ASSESSMENT SCALE; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SEX DIFFERENCE; SOCIAL SUPPORT; SOCIOECONOMICS; SYMPTOM ASSESSMENT; INDIVIDUALITY; LONGITUDINAL STUDY; MIDDLE AGED; NEOPLASMS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; QUESTIONNAIRE;

FEMALE; HUMANS; INDIVIDUALITY; INDIVIDUALIZED MEDICINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; QUALITY OF LIFE; QUESTIONNAIRES; SYMPTOM ASSESSMENT;

EID: 84904604275     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28699     Document Type: Article

References (65)

1. Esther Kim JE, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C,. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage. 2009; 37: 715-736.
2. Pud D, Ben Ami S, Cooper BA, et al. The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. J Pain Symptom Manage. 2008; 35: 162-170.
3. Dodd MJ, Cho MH, Cooper BA, et al. Identification of latent classes in patients who are receiving biotherapy based on symptom experience and its effect on functional status and quality of life. Oncol Nurs Forum. 2011; 38: 33-42.
4. Dodd MJ, Cho MH, Cooper BA, Miaskowski C,. The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs. 2010; 14: 101-110.
5. Illi J, Miaskowski C, Cooper B, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine. 2012; 58: 437-447.
6. Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncol Nurs Forum. 2006; 33: E79-E89.
7. Ferreira KA, Kimura M, Teixeira MJ, et al. Impact of cancer-related symptom synergisms on health-related quality of life and performance status. J Pain Symptom Manage. 2008; 35: 604-616.
8. Gwede CK, Small BJ, Munster PN, Andrykowski MA, Jacobsen PB,. Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach. Support Care Cancer. 2008; 16: 925-933.
9. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A: 1326-1336.
10. National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: The National Academies Press; 2011.
11. Anders CK, Zagar TM, Carey LA,. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am. 2013; 27: 737-749.
12. Lam SW, Jimenez CR, Boven E,. Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev. 2014; 40: 129-138.
13. Yu Y, He J,. Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med. 2013; 7: 157-171.
14. Ogino S, Fuchs CS, Giovannucci E,. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012; 12: 621-628.
15. Karnofsky D, Abelmann WH, Craver LV, Burchenal JH,. The use of nitrogen mustard in the palliative treatment of cancer. Cancer. 1948; 1: 634-656.
16. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN,. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003; 49: 156-163.
17. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994; 3: 183-189.
18. Ware J Jr, Kosinski M, Keller SD,. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34: 220-233.
19. Ferrell BR, Wisdom C, Wenzl C,. Quality of life as an outcome variable in the management of cancer pain. Cancer. 1989; 63: 2321-2327.
20. Padilla GV, Grant MM,. Quality of life as a cancer nursing outcome variable. ANS Adv Nurs Sci. 1985; 8: 45-60.
21. Padilla GV, Presant C, Grant MM, Metter G, Lipsett J, Heide F,. Quality of life index for patients with cancer. Res Nurs Health. 1983; 6: 117-126.
22. Muthen B, Shedden K,. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics. 1999; 55: 463-469.
23. Vermunt JK, Magdison J,. Latent Class Cluster Analyses. New York: Cambridge University Press; 2002.
24. Collins LM, Lanza ST,. Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Science. Hoboken, NJ: John Wiley & Sons; 2010.
25. Nylund K, Bellmore A, Nishina A, Graham S,. Subtypes, severity, and structural stability of peer victimization: what does latent class analysis say? Child Dev. 2007; 78: 1706-1722.
26. Nylund KL, Asparouhov T, Muthen BO,. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Modeling. 2007; 14: 535-569.
27. Celeux G, Soromenho G,. An entropy criterion for assessing the number of clusters in a mixture model. J Classification. 1996; 13: 195-212.
28. Muthen LK, Muthen BO,. Mplus User's Guide. 7th ed. Los Angeles, CA: Muthen & Muthen; 2012.
29. Muthen LK, Muthen BO,. Mplus (Version 7). Los Angeles, CA: Muthen & Muthen; 2012.
30. Dunn LB, Aouizerat BE, Langford DJ, et al. Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers. Eur J Oncol Nurs. 2013; 17: 346-353.
31. Miaskowski C, Cooper BA, Dhruva A, et al. Evidence of associations between cytokine genes and subjective reports of sleep disturbance in oncology patients and their family caregivers. PLoS One. 2012; 7: e40560.
32. McCann B, Miaskowski C, Koetters T, et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012; 13: 425-437.
33. Rothman KJ,. No adjustments are needed for multiple comparisons. Epidemiology. 1990; 1: 43-46.
34. Cataldo JK, Paul S, Cooper B, et al. Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer. 2013; 13: 6.
35. Ritchie C, Dunn LB, Paul SM, et al. Differences in the symptom experience of older oncology outpatients [published online ahead of print July 31, 2013 ]. J Pain Symptom Manage. p ii: S0885-392400334-5. doi: 10.1016/j.jpainsymman. 2013.05.017.
36. Townsley C, Pond GR, Peloza B, et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol. 2005; 23: 3802-3810.
37. Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007; 25: 1272-1276.
38. Bower JE, Low CA, Moskowitz JT, Sepah S, Epel E,. Benefit finding and physical health: positive psychological changes and enhanced allostasis. Soc Personal Psychol Compass. 2008; 2: 223-244.
39. Sprangers MA, Schwartz CE,. The challenge of response shift for quality-of-life-based clinical oncology research. Ann Oncol. 1999; 10: 747-749.
40. Schwartz CE, Sprangers MA,. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999; 48: 1531-1548.
41. Baldwin CM, Grant M, Wendel C, et al. Gender differences in sleep disruption and fatigue on quality of life among persons with ostomies. J Clin Sleep Med. 2009; 5: 335-343.
42. Cheung WY, Le LW, Gagliese L, Zimmermann C,. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer. 2011; 19: 417-423.
43. Giesinger J, Kemmler G, Mueller V, et al. Are gender-associated differences in quality of life in colorectal cancer patients disease-specific? Qual Life Res. 2009; 18: 547-555.
44. Heinonen H, Volin L, Uutela A, Zevon M, Barrick C, Ruutu T,. Gender-associated differences in the quality of life after allogeneic BMT. Bone Marrow Transplant. 2001; 28: 503-509.
45. Miaskowski C,. Gender differences in pain, fatigue, and depression in patients with cancer. J Natl Cancer Inst Monogr. 2004; 32: 139-143.
46. Fu OS, Crew KD, Jacobson JS, et al. Ethnicity and persistent symptom burden in breast cancer survivors. J Cancer Surviv. 2009; 3: 241-250.
47. Luckett T, Goldstein D, Butow PN, et al. Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2011; 12: 1240-1248.
48. Hann D, Baker F, Denniston M, et al. The influence of social support on depressive symptoms in cancer patients: age and gender differences. J Psychosom Res. 2002; 52: 279-283.
49. Kurtz ME, Kurtz JC, Stommel M, Given CW, Given B,. Predictors of depressive symptomatology of geriatric patients with lung cancer-a longitudinal analysis. Psychooncology. 2002; 11: 12-22.
50. Simpson JS, Carlson LE, Beck CA, Patten S,. Effects of a brief intervention on social support and psychiatric morbidity in breast cancer patients. Psychooncology. 2002; 11: 282-294.
51. Akin S, Can G, Aydiner A, Ozdilli K, Durna Z,. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 2010; 14: 400-409.
52. Eversley R, Estrin D, Dibble S, Wardlaw L, Pedrosa M, Favila-Penney W,. Post-treatment symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum. 2005; 32: 250-256.
53. Sarna L,. Correlates of symptom distress in women with lung cancer. Cancer Pract. 1993; 1: 21-28.
54. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR,. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002; 77: 371-383.
55. Osoba D,. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer Suppl. 1999; 12: 132-137.
56. Reyes-Gibby CC, Shete S, Yennurajalingam S, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage. 2009; 38: 894-902.
57. Reyes-Gibby CC, El Osta B, Spitz MR, et al. The influence of tumor necrosis factor-alpha-308 G/A and IL-6-174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3262-3267.
58. Felger JC, Cole SW, Pace TW, et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol Med. 2012; 42: 1591-1603.
59. Jim HS, Park JY, Permuth-Wey J, et al. Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun. 2012; 26: 1030-1036.
60. Reinertsen KV, Grenaker Alnaes GI, Landmark-Hoyvik H, et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun. 2011; 25: 1376-1383.
61. Collado-Hidalgo A, Bower JE, Ganz PA, Irwin MR, Cole SW,. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. 2008; 22: 1197-1200.
62. Miaskowski C, Dodd M, Lee K, et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manage. 2010; 40: 531-544.
63. Aouizerat BE, Dodd M, Lee K, et al. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs. 2009; 11: 27-41.
64. Kim JM, Kim SW, Stewart R, et al. Serotonergic and BDNF genes associated with depression 1 week and 1 year after mastectomy for breast cancer. Psychosom Med. 2012; 74: 8-15.
65. Schillani G, Martinis E, Capozzo MA, et al. Psychological response to cancer: role of 5-HTTLPR genetic polymorphism of serotonin transporter. Anticancer Res. 2010; 30: 3823-3826.